Lithium and Thyroid Cancer Risk
Lithium does not increase the risk of thyroid cancer, and there is no evidence supporting a causal relationship between lithium therapy and thyroid malignancy. 1, 2, 3
Cancer Risk Evidence
The available evidence consistently shows that thyroid cancer is rare in patients on lithium therapy:
- A 15-year prospective follow-up study of 150 lithium patients found only one case of papillary thyroid carcinoma over 976 patient-years of observation 3
- Death from cancer in 30,000 lithium-treated patients did not differ from the general population 4
- While isolated case reports exist 5, these represent anecdotal observations without establishing causation
- The FDA drug label for lithium does not list thyroid cancer as a known adverse effect 1
The few thyroid cancers observed in lithium patients likely represent coincidental findings at rates consistent with the general population, not a drug-induced phenomenon 2, 3.
Thyroid Monitoring Protocol for Lithium Patients
Baseline assessment before initiating lithium:
- TSH level
- Free T4 and T3
- Anti-thyroid peroxidase (TPO) antibodies
- Thyroid ultrasound (to document baseline thyroid size and detect pre-existing nodules) 6, 7
During the first year of treatment:
- Repeat full thyroid panel (TSH, free T4, TPO antibodies) at 3 months 1
- Repeat assessment at 12 months 6, 7
Long-term monitoring (after first year):
- Annual TSH measurement is sufficient for most patients 7, 8
- More frequent monitoring (every 4-6 months) is indicated for:
Ultrasound follow-up:
- Repeat thyroid ultrasound every 2-3 years to monitor for goiter development or new nodules 7
- If nodules >1 cm are detected and appear suspicious on ultrasound, proceed with fine-needle aspiration per standard thyroid nodule guidelines 9
Common Thyroid Effects of Lithium (Not Cancer)
The actual thyroid complications of lithium are:
- Hypothyroidism: occurs in approximately 20% of patients, with an annual incidence rate of 1.5% 2, 3, 8
- Goiter: develops in up to 40% of patients 2
- Subclinical hypothyroidism: more common than overt hypothyroidism 8
Risk factors for developing hypothyroidism include:
- Female sex
- Younger age at lithium initiation 8
- Presence of thyroid autoantibodies (8.4-fold increased risk) 3
- Higher lithium serum levels 8, 10
- Physical comorbidities 8
Management of Lithium-Induced Hypothyroidism
If hypothyroidism develops, do NOT discontinue lithium. 1, 7 Instead:
- Initiate levothyroxine replacement therapy
- Target TSH within normal range (0.5-2.0 mIU/L for general population) 1
- Continue lithium therapy, as it remains the gold standard for bipolar disorder prophylaxis 7
- The presence of thyroid dysfunction should not contraindicate lithium use 7
Critical Pitfall to Avoid
Recent case reports highlight that chronic lithium therapy can cause severe histologic thyroid changes that mimic high-grade thyroid carcinoma 11. These changes include:
- Intersecting fibrosis
- Nuclear pleomorphism and hyperchromasia
- Pseudopapillary formations
- Giant cell formation
However, these lithium-induced changes lack mitotic activity and necrosis—features required for diagnosing poorly differentiated or high-grade thyroid carcinoma under 2022 WHO criteria 11. Always communicate lithium history to pathologists to prevent misdiagnosis and unnecessary completion thyroidectomy 11.